(Reuters) – Roche said nine-month sales slipped 6% to 44.1 billion Swiss francs ($49.1 billion), hit by a sharp decline in sales of COVID-19 products and as a strong Swiss franc weighed on the value of overseas sales.
In a statement on Thursday, the Swiss drugs and diagnostics maker also confirmed its full-year guidance.
(Reporting by Ludwig Burger, Editing by Friederike Heine)
